Proprietary Formulations and Drug Candidates
Pipeline of Proprietary Drug Candidates
Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of indication-specific drug candidates that are in various stages of clinical development, registration, and commercialization
These cannabinoid-based drug candidates are designed to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.
Trunerox™ – 10% CBD (100 mg/ml Cannabidiol)
Trunerox™ is a pharmaceutical drug with proprietary formulation manufactured under GMP standards and utilizing the Company’s API. Clinical indications show Trunerox™ shows potential as an adjunctive treatment for seizures associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS).
Marketing authorization has been obtained in Colombia by INVIMA in Q1, 2024. Commercialization in Colombia is expected for late 2024 with opportunities to expand into other South and Central American markets.”